Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male japanese subjects

Publication | Closed Access

DOI

Citations

References

2010

Year

Akiko Sarashina, Shogo Sesoko, Mitsuyoshi Nakashima, Naoyuki Hayashi, Atsushi Taniguchi, Yoshiharu Horie, Eva U. Graefe-Mody, Hans‐Juergen Woerle, Klaus A. Dugi

Clinical Therapeutics

Diabetes ManagementMedicineDiabetesType 2PharmacotherapyDiabetes MellitusDipeptidyl Peptidase-4 InhibitorPharmacologyDrug Discovery